Sana Biotechnology (SANA) Asset Writedowns and Impairment (2024)

Sana Biotechnology (SANA) reported Asset Writedowns and Impairment of $1.9 million for Q4 2024.

Sana Biotechnology (SANA) Asset Writedowns and Impairment (2024) Analysis & Trends

Sana Biotechnology (SANA) has 1 years of Asset Writedowns and Impairment data on file, last reported at $1.9 million in Q4 2024.

For the quarter ending Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (changed N/A YoY), and the FY2025 full-year result was $44.6 million, up 2259.12% from the prior year.
Asset Writedowns and Impairment steadied at $1.9 million in Q4 2024.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.9 million in Q4 2024 to a low of $1.9 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Sana Biotechnology	923.31 Mn	923.31 Mn	-

Download Data

Date	Value
Dec 31, 2024	1.89 Mn
Dec 31, 2024	1.89 Mn